Chinese PD-L1 inhibitor
Nov 05, 2026
After KEYTRUDA: How PD-1 and PD-L1 Inhibitors Are Being Redesigned for a Post-Patent Era
Summary The PD-1 and PD-L1 inhibitors list now spans a dozen or more approved drugs. Clinical efficacy is broadly similar across them, so winners are decided by trial breadth, indication coverage, and convenience. Subcutaneous atezolizumab (2024), nivolumab (2024), and pembrolizumab (Keytruda Qlex, September...
Read More...
Jul 27, 2026
PD-1 Inhibitors: Which Companies Are Winning the Immunotherapy Race?
Summary The PD-1 inhibitors market is led by Merck’s KEYTRUDA and Bristol Myers Squibb’s OPDIVO, which together still dominate global revenue and remain the standard-bearers in the category. Challenger PD-1 drugs such as Sanofi/Regeneron’s LIBTAYO, GSK’s JEMPERLI, and Incyte’s ZYNYZ have carved out positions...
Read More...
Jun 03, 2024
Rapid Global Expansion of Chinese PD-1/PD-L1 Key Players
Immune checkpoint inhibitors (ICIs) are currently among the most widely used treatments for cancer. Chinese pharmaceutical companies have been making significant strides in developing PD-1 and PD-L1 inhibitors, used to treat various cancers. Several of these companies are now entering or planning to enter the US an...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
